Dr. Lerner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
223 Madison Rd
Scarsdale, NY 10583Phone+1 415-637-1636
Education & Training
University of California (San Francisco)Fellowship, Cardiovascular Disease, 1995 - 1999- University of California (San Francisco)Internship, Internal Medicine, 1990 - 1991
- University of California San Francisco School of MedicineClass of 1990
Certifications & Licensure
NY State Medical License 2001 - 2026
CA State Medical License 2019 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Clinical Trials
- TYRX™ Envelope for Prevention of Infection Following Replacement With a CRT or ICD Start of enrollment: 2010 Jan 01
Publications & Presentations
PubMed
- 21 citationsSurgical ablation of atrial fibrillation concomitant to coronary-artery bypass grafting provides cost-effective mortality reductionJ. Scott Rankin, Daniel J. Lerner, Mary Jo Braid-Forbes, Michelle M. McCrea, Vinay Badhwar
The Journal of Thoracic and Cardiovascular Surgery. 2020-09-01 - 32 citationsPrevalence of Atrial Fibrillation before Cardiac Surgery and Factors Associated with Concomitant AblationPatrick M. McCarthy, Charles J. Davidson, Jane Kruse, Daniel J. Lerner, Mary Jo Braid-Forbes
The Journal of Thoracic and Cardiovascular Surgery. 2020-06-01 - 23 citationsOne-year mortality and costs associated with surgical ablation for atrial fibrillation concomitant to coronary artery bypass graftingJ. Scott Rankin, Daniel J. Lerner, Mary Jo Braid-Forbes, Michael A. J. Ferguson, Vinay Badhwar
European Journal of Cardio-Thoracic Surgery. 2017-09-01
Grant Support
- Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetesSENSEION THERAPEUTICS, INC.2023–2026
- Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetesSENSEION THERAPEUTICS, INC.2023–2026
- Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetesSENSEION THERAPEUTICS, INC.2023–2026
- Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetesSENSEION THERAPEUTICS, INC.2023–2026
- Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetesSENSEION THERAPEUTICS, INC.2023–2026
- Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetesSENSEION THERAPEUTICS, INC.2023–2026
- Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetesSENSEION THERAPEUTICS, INC.2023–2026
- Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetesSENSEION THERAPEUTICS, INC.2023–2026
- Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetesSENSEION THERAPEUTICS, INC.2023–2026
- Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 DiabetesSENSEION THERAPEUTICS, INC.2021–2025
- Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitisSENSEION THERAPEUTICS, INC.2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
